Abstract:Abstract Background Postmenopausal osteoporosis is a chronic metabolic bone disease caused by excessive osteoclast formation and function. Targeting osteoclast differentiation and activity can modulate bone resorption and alleviate osteoporosis. Cirsilineol, an active constituent of vestita Wall, has shown numerous biological activities and has been used to treat many metabolic diseases. However, whether cirsilineol inhibits osteoclast activity and prevents postmenopausal osteoporosis still remain unknown. Materials and methods Primary bone marrow macrophages (BMMs) and RAW264.7 cells were used. Osteoclast activity was measured by TRAP staining, F-actin staining, and bone resorption assay after BMMs were treated with cirsilineol at concentrations of 0, 1, 2.5 and 5 µM. RT-PCR and western blotting were performed to evaluate the expression of osteoclast-related genes. In addition, female C57BL/6 mice underwent OVX surgery and were treated with cirsilineol (20mg/kg) to demonstrate the effect of cirsilineol on osteoporosis. Results Cirsilineol significantly inhibited receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclast differentiation in a concentration- and time-dependent manner, respectively. Additionally, cirsilineol inhibited F-actin ring formation, thus reducing the activation of bone resorption ability. Cirsilineol suppressed the expression of osteoclast-related genes and proteins via blocking nuclear factor (NF)-κβ, ERK, and p38 signaling cascades. More importantly, cirsilineol treatment in mice with osteoporosis alleviated osteoclasts hyperactivation and bone mass loss caused by estrogen depletion. Conclusion In this study, the protective effect of cirsilineol on osteoporosis has been investigated for the first time. In conclusion, our findings prove the inhibitory effect of cirsilineol on osteoclast activity via NK-κβ/ERK/p38 signaling pathways and strongly suggest that the application of cirsilineol can be proposed as a potential therapeutic strategy.

Matrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-induced Osteoclastogenesis

Alpinetin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Modulating NFATc1 Transcription and Lysosomal Function

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NF-κb/ERK/p38 signaling pathways

Matrine Induces Caspase-Dependent Apoptosis in Human Osteosarcoma Cells in Vitro and in Vivo Through the Upregulation of Bax and Fas/FasL and Downregulation of Bcl-2

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NK-κβ/ERK/p38 signaling pathways

Astilbin Prevents Bone Loss in Ovariectomized Mice Through the Inhibition of RANKL‐induced Osteoclastogenesis

Madecassoside Inhibits Estrogen Deficiency‐induced Osteoporosis by Suppressing RANKL‐induced Osteoclastogenesis

A Novel Anti-Osteoporotic Agent That Protects Against Postmenopausal Bone Loss by Regulating Bone Formation and Bone Resorption.

Tectoridin Inhibits Osteoclastogenesis and Bone Loss in a Murine Model of Ovariectomy-Induced Osteoporosis

Oxymatrine Attenuates Osteoclastogenesis via Modulation of ROS-Mediated SREBP2 Signaling and Counteracts Ovariectomy-Induced Osteoporosis

Retraction Note To: Matrine Derivate MASM Uncovers a Novel Function for Ribosomal Protein S5 in Osteoclastogenesis and Postmenopausal Osteoporosis

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways

Inhibitory Effects Of Morinda Officinalis Extract On Bone Loss In Ovariectomized Rats

The use of matrine to inhibit osteosarcoma cell proliferation via the regulation of the MAPK/ERK signaling pathway

L‐tetrahydropalmatine Suppresses Osteoclastogenesis in Vivo and in Vitro Via Blocking RANK‐TRAF6 Interactions and Inhibiting NF‐κB and MAPK Pathways

Matrine Reduces Traumatic Heterotopic Ossification in Mice by Inhibiting M2 Macrophage Polarization Through the MAPK Pathway

Cinnamtannin B-1 Prevents Ovariectomy-Induced Osteoporosis via Attenuating Osteoclastogenesis and ROS Generation

Beneficial Effect of Pristimerin Against the Development of Osteoporosis in Ovariectomy-Induced Osteoporosis Rats by the RANKL/TRAF6/NF-κB Pathway.

Maslinic Acid Suppresses Osteoclastogenesis And Prevents Ovariectomy-Induced Bone Loss By Regulating Rankl-Mediated Nf-Kappa B And Mapk Signaling Pathways

Morusin induces osteogenic differentiation of bone marrow mesenchymal stem cells by canonical Wnt/-catenin pathway and prevents bone loss in an ovariectomized rat model